|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
100 项与 Epigenetix 相关的临床结果
0 项与 Epigenetix 相关的专利(医药)
100 项与 Epigenetix 相关的药物交易
100 项与 Epigenetix 相关的转化医学